SecBot SecBot

Increasing Access to Biosimilars Act of 2023

H.R. 1352 Rep. Richard Hudson (R-NC-9) In committee
Bill text PDF
  1. Introduced Mar 3
  2. Committee Mar 3
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 3, 2023Next: House vote
680d ago Dec 17, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
4companies, 5 filings
Subscribe to see spend
Member trades
14trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

4 companies
Companies by sector
Biotech & Pharma 3Financials 1
Search all 4 companies, their asks and price moves Subscribe

Summary

Increasing Access to Biosimilars Act of 2023

Full summary1 paragraphs

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Library of Congress summary, Mar 3, 2023

Summary versions
  • Introduced in HouseMar 3, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.